title: Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
abstract: We investigated the effect of laquinimod on inflammatory demyelination, axonal damage, cytokine profiles and migratory capacities of lymphocytes in C57BL/6 mice with active EAE induced with MOG(35-55) peptide. The mice were treated at disease induction and after disease onset. Spinal cords were assessed histologically. Cytokines and adhesive properties were analyzed in splenocytes. Preventive and therapeutic laquinimod treatment reduced clinical signs, inflammation, and demyelination. VLA-4-mediated adhesiveness and pro-inflammatory cytokines such as IL-17 were down-regulated in treated animals. Within lesions, treated mice showed similar axonal densities, but less acute axonal damage than controls. Laquinimod might thus protect myelin and axons by decreasing pro-inflammatory cytokines and impairing the migratory capacity of lymphocytes.
authors.affiliation: Department of Neuropathology, University Medical Center, Georg-August University, Göttingen, Germany. chrwegner@gmx.de
authors.forename: Christiane
authors.initials: C
authors.lastname: Wegner
authors.forename: Christine
authors.initials: C
authors.lastname: Stadelmann
authors.forename: Ramona
authors.initials: R
authors.lastname: Pförtner
authors.forename: Emanuel
authors.initials: E
authors.lastname: Raymond
authors.forename: Sara
authors.initials: S
authors.lastname: Feigelson
authors.forename: Ronen
authors.initials: R
authors.lastname: Alon
authors.forename: Bracha
authors.initials: B
authors.lastname: Timan
authors.forename: Liat
authors.initials: L
authors.lastname: Hayardeny
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Brück
mesh_terms: D000818:Animals; D001369:Axons / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D003711:Demyelinating Diseases / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D018836:Inflammation Mediators / Q000627:therapeutic use*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D015363:Quinolones / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000473:pathology*
chemical_list: D018836:Inflammation Mediators; D020381:Interleukin-17; D015363:Quinolones; C476223:laquinimod